A Phase 1/2 interventional study of NMS-03592088 in Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML), sponsored by Nerviano Medical Sciences. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Nerviano Medical Sciences · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 67 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 140th largest by enrollment of the 196 interventional ones that give a count, is one of 20 that started in 2019, is one of 41 in phase 1/2, and was the 123rd registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18–75 · Healthy volunteers
Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Sites in Italy
Ages 6 mo–75 yrs
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
AbbVie · Sites in Italy, United States, Australia and 4 more countries
Ages 6 mo–17 yrs
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 100 · Phase 3 62 · Phase 4 1
First in 1993; this study’s year is marked. 20 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 120 across the 196 interventional studies, 202 across the 31 observational. Of the 140 that completed or were terminated, 77 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 229 have an industry lead sponsor. The 10 most frequent:
Nerviano Medical Sciences is the lead sponsor of 15 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
Nerviano Medical Sciences has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
14 of the studies in Leukemia, Myeloid, Acute with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04232241Universitätsklinikum Hamburg-EppendorfMatched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | 2026-11-22 |
Add all 14 to your calendar (.ics) → With an account.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
US only:
Other protocol specific inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase I Dose Escalation * Schedule A - Starting dose of 20 mg/day * Schedule B - Starting dose of 120 mg/day Only one dose level open for enrollment except EU backfill cohorts. Phase II Dose Expansion (Exploratory) - (EU) Recommended Phase II Dose (RP2D) of NMS-03592088 in Phase 1 * Cohort 1: Patients who have failed standard of care including venetoclax and gilteritinib based therapies * Cohort 2: Patients who have failed standard of care
Drug: NMS-03592088
Route of administration: Oral
Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs)
DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
Time frame: From screening to end of first 28-days cycle (47 months)
Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi).
CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.
Time frame: At Screening; Day 1 of Cycle 2 and Cycle 3; and Day 1 at subsequent even cycle; up to End of Treatment visit (within 7 days of the final dose of study drug), up to 17 months
Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria
TEAE with maximum Common Terminology Criteria (CTC) grade (graded by NCI CTCAE Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Time frame: Adverse events were collected from screening visit and assessed up to 18 months
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax), Last Measurable Concentration (Clast), and Average Concentration (Cavg) of NMS-03592088
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Pharmacokinetic Parameters: Time to Maximum Plasma Concentration (Tmax), Time to Last Measurable Concentration (Tlast), and Terminal Elimination Half-life (t½,z) of NMS-03592088
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 1 and 21 Schedule B: Day 1 and 28
Pharmacokinetic Parameter: Area Under the Concentration-time Curve to the Last Measurable Concentration (AUClast) and Area Under the Concentration-time Curve From Time Zero to 24 Hour (AUC0-24) of NMS-03592088
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28
Pharmacokinetic Parameters: Apparent Volume of Distribution (V/F) and Apparent Volume of Distribution at Steady State (Vss/F)
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 21
Pharmacokinetic Parameters: Apparent Plasma Clearance (CL/F) and Apparent Plasma Clearance at Steady State (CLss/F)
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 1 and Day 21 Schedule B: Day 1 and Day 28 CL/F: Evaluation of CL/F for Day 1 of all arms in Schedule A and Schedule B and Day 28 of Schedule B has not been performed
Pharmacokinetic Parameters: Accumulation Ratios (RA) for AUC0-24 and Cmax
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%).
Time frame: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Accumulation ratios (RA) for AUC0-24 and Cmax on Day 1 of all arms in Schedule A and Schedule B has not been performed.
Pharmacokinetic Parameters: Fraction Excreted Unchanged (FE) of NMS-03592088
Urine samples were collected and used for pharmacokinetics (PK) assessments. Only cohorts with available data are presented. The assessment was performed only during the Phase I of the study. Mean values of PK parameters are presented with the coefficient of variation (CV%)
Time frame: Schedule A: Day 21 Schedule B: Day 28 Evaluation of Fraction excreted unchanged (FE) for Arms 20, 40, 80, 120 and 180 mg of Schedule A and Arm 360+150 mg of Schedule B has not been performed.
Best Response Rate for Participants With Acute Myeloblastic Leukemia (AML).
For participants with AML diagnosis the number and percentage of participants with best response achieved on treatment in the following categories: CR, CRi, CRh, PR, MLFS, SD, No Response and Progressive Disease (PD). CR= complete response; CRh= Complete Remission with Partial Hematologic Recovery, CRi= Complete Remission with Incomplete Hematologic Recovery; CRc= Complete Remission Rate; MLFS= Morphologic leukemia free state; ORR= Overall Response Rate; PR= Partial Remission; SD= Stable Disease
Time frame: From the date of treatment initiation up to end of study (approximately 1.5 years)
For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR)
Number of participants who achieved a CR as Best Response.
Time frame: From the date of first response up to end of study (approximately 1.5 years)
For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate
Defined as the number of participants who achieved a CR or CRh or CRi as best response, divided by the number of participants in the analysis population.
Time frame: From the date of first response up to end of study (approximately 1.5 years)
For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR)
Defined as the number of participants who achieved CRi or MLFS as best response, divided by the number of participants in the analysis population.
Time frame: From the date of first response up to end of study (approximately 1.5 years)
Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation
Defined as proportion of participants bridged to hemopoietic stem cell transplantation
Time frame: From the date of first response up to end of study (approximately 1.5 years)
| Milestone | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 6 | 4 | 5 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 6 | 4 | 5 | 10 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Disease progression or relapse | 3 | 2 | 2 | 3 | 2 | 1 | 8 | 1 | 3 | 0 | 2 | 1 | 4 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Eligibility for hemopoietic stem cell transplantation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: First cycle dose limiting toxicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Unacceptable drug related toxicities incompatible with continuation of nms-03592088 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Myasthenic syndrome with systemic and/or bulbar impairment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
DLTs were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.
| Participants | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase I - Number of Participants With Drug Related First-cycle Dose Limiting Toxicities (DLTs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
CR = complete remission; CRc = composite complete remission rate; CRh = complete remission with partial hematologic recovery, CRi = complete remission with incomplete hematologic recovery; MLFS = morphologic leukemia free state; ORR = overall response rate; SD = stable disease Categories defined by the 2022 European LeukemiaNet (ELN) recommendations.
| Participants | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|
| Phase II - Number of Participants Who Achieved Composite Complete Remission (CRc) Rate i.e. Complete Remission (CR) + Complete Remission With Incomplete Hematologic Recovery (CRi). | 0 | 1 |
TEAE with maximum Common Terminology Criteria (CTC) grade (graded by NCI CTCAE Version 5.0) experienced by each participant is presented. If an AE was reported for a participant more than once during treatment, the worst CTC Grade is presented here. Phase 2 started before Phase 1 completed. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
| Participants | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent Adverse Events (TEAEs) Graded by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 5.0 Criteria | 3 | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 6 | 4 | 15 |
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| μM | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B: 360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmax: Day 1 | 0.00469 ± 12.9 | 0.0174 ± 19.1 | 0.0262 ± 33.6 | 0.0388 ± 53.1 | 0.118 ± 43.9 | 0.211 ± 84.2 | 0.207 ± 55.5 | 0.240 ± 79.8 | 0.0907 ± 82.4 | 0.124 ± 42.9 | 0.183 ± 51.1 | 0.0995 ± 43.9 |
| Cmax: Day 21 | 0.0523 ± 52.5 | 0.0526 ± 32.4 | 0.0896 ± 22.6 | 0.125 ± 45.9 | 0.320 ± 64.0 | 0.553 ± 41.9 | 0.444 ± 50.6 | 0.467 ± 40.9 | — | — | — | — |
| Cmax: Day 28 | — | — | — | — | — | — | — | — | 0.266 ± 42.0 | 0.354 ± 46.5 | 0.462 ± 54.4 | 0.168 ± 37.7 |
| Clast: Day 1 | 0.00363 ± 38.2 | 0.00819 ± 55.5 | 0.0132 ± 19.0 | 0.0188 ± 45.7 | 0.0309 ± 52.3 | 0.0568 ± 46.5 | 0.137 ± 68.8 | 0.0930 ± 75.7 | 0.0296 ± 37.2 | 0.0536 ± 79.4 | 0.0957 ± 19.7 | 0.0816 ± 43.6 |
| Clast: Day 21 | 0.0151 ± 59.7 | 0.00902 ± 102 | 0.0199 ± 77.2 | 0.0230 ± 81.4 | 0.0548 ± 48.7 | 0.0876 ± 20.1 | 0.0831 ± 86.9 | 0.215 ± 80.9 | — | — | — | — |
| Clast: Day 28 | — | — | — | — | — | — | — | — | 0.141 ± 39.5 | 0.293 ± 53.1 | 0.322 ± 53.3 | 0.116 ± 20.3 |
| Cavg: Day 1 | 0.00385 ± 19.9 | 0.0102 ± 32.9 | 0.0168 ± 22.9 | 0.0230 ± 34.1 | 0.0591 ± 65.9 | 0.0931 ± 54.1 | 0.0905 ± 61.2 | 0.143 ± 78.6 | 0.0455 ± 61.5 | 0.0554 ± 27.9 | 0.0883 ± 61.1 | 0.0172 ± 46.4 |
| Cavg: Day 21 | 0.0423 ± 41.3 | 0.0392 ± 56.3 | 0.0740 ± 30.2 | 0.0890 ± 32.0 | 0.200 ± 37.3 | 0.421 ± 27.1 | 0.349 ± 50.4 | 0.351 ± 54.6 | — | — | — | — |
| Cavg: Day 28 | — | — | — | — | — | — | — | — | 0.183 ± 36.1 | 0.277 ± 48.2 | 0.378 ± 56.2 | 0.118 ± 69.8 |
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| hour | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B: 360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tmax: Day 1 | 6.00 ± 0 | 3.33 ± 69.3 | 10.4 ± 90.4 | 3.01 ± 87.7 | 1.67 ± 35.0 | 3.02 ± 65.8 | 3.78 ± 41.7 | 4.66 ± 24.4 | 4.00 ± 57.7 | 3.65 ± 41.7 | 3.25 ± 83.9 | 2.73 ± 46.5 |
| Tmax: Day 21 | 1.67 ± 125 | 3.00 ± 88.2 | 4.00 ± 50.0 | 3.33 ± 69.3 | 9.31 ± 136 | 4.00 ± 44.7 | 5.41 ± 108 | 4.41 ± 37.7 | — | — | — | — |
| Tmax: Day 28 | — | — | — | — | — | — | — | — | 2.33 ± 58.6 | 6.00 ± 49.5 | 2.80 ± 63.9 | 4.33 ± 34.7 |
| Tlast: Day 1 | 23.5 ± 1.05 | 22.5 ± 3.23 | 21.1 ± 11.9 | 22.7 ± 7.15 | 22.6 ± 13.0 | 23.4 ± 2.14 | 16.4 ± 50.6 | 22.4 ± 6.78 | 23.2 ± 2.79 | 20.0 ± 34.8 | 18.5 ± 45.6 | 5.96 ± 1.29 |
| Tlast: Day 21 | 160 ± 35.2 | 194 ± 0.998 | 170 ± 25.4 | 170 ± 43.8 | 120 ± 39.7 | 160 ± 31.1 | 183 ± 26.6 | 120 ± 60.2 | — | — | — | — |
| Tlast: Day 28 | — | — | — | — | — | — | — | — | 24.0 ± 0 | 22.0 ± 22.8 | 24.0 ± 0.309 | 17.9 ± 57.5 |
| t½,z: Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| t½,z: Day 21 | 89.5 ± 19.5 | 79.5 ± 35.2 | 71.7 ± 4.35 | 68.4 ± 18.2 | 57.3 ± 32.3 | 63.7 ± 24.0 | 77.3 ± 16.4 | 150 ± 0 | — | — | — | — |
| t½,z: Day 28 | — | — | — | — | — | — | — | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| h·μM | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B: 360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUClast: Day 1 | 0.0923 ± 19.9 | 0.244 ± 32.9 | 0.402 ± 22.9 | 0.551 ± 34.1 | 1.43 ± 66.7 | 2.23 ± 54.1 | 2.17 ± 61.2 | 3.44 ± 78.6 | 1.09 ± 61.5 | 1.33 ± 27.9 | 2.12 ± 60.8 | 0.412 ± 46.4 |
| AUClast: Day 21 | 4.10 ± 53.3 | 3.96 ± 71.9 | 6.31 ± 29.0 | 6.98 ± 35.3 | 13.4 ± 54.4 | 34.5 ± 28.2 | 31.4 ± 59.1 | 23.7 ± 80.1 | — | — | — | — |
| AUClast: Day 28 | — | — | — | — | — | — | — | — | 4.39 ± 36.1 | 6.67 ± 48.7 | 9.09 ± 56.5 | 2.84 ± 69.9 |
| AUC0-24: Day 1 | 0.0923 ± 19.9 | 0.244 ± 32.9 | 0.402 ± 22.9 | 0.551 ± 34.1 | 1.42 ± 65.9 | 2.23 ± 54.1 | 2.17 ± 61.2 | 3.44 ± 78.6 | 1.09 ± 61.5 | 1.33 ± 27.9 | 2.12 ± 61.1 | 0.412 ± 46.4 |
| AUC0-24: Day 21 | 1.02 ± 41.3 | 0.941 ± 56.3 | 1.78 ± 30.2 | 2.14 ± 32.0 | 4.80 ± 37.3 | 10.1 ± 27.1 | 8.37 ± 50.4 | 8.43 ± 54.6 | — | — | — | — |
| AUC0-24: Day 28 | — | — | — | — | — | — | — | — | 4.39 ± 36.1 | 6.65 ± 48.2 | 9.07 ± 56.2 | 2.83 ± 69.8 |
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| L | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V/F: Day 21 | 844 ± 32.5 | 2030 ± 39.7 | 1940 ± 31.3 | 2680 ± 50.9 | 1630 ± 31.0 | 1070 ± 17.5 | 1770 ± 36.0 | 1070 ± 0 | — | — | — | — |
| Vss/F: Day 21 | 4880 ± 21.8 | 9440 ± 20.3 | 8800 ± 22.8 | 10900 ± 39.4 | 5810 ± 25.8 | 4710 ± 37.0 | 8270 ± 37.0 | 10500 ± 0 | — | — | — | — |
Plasma samples were collected and used for pharmacokinetics (PK) assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| L/h | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CL/F: Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| CL/F: Day 21 | 7.02 ± 53.1 | 20.4 ± 57.1 | 19.0 ± 34.6 | 27.6 ± 52.5 | 21.4 ± 46.5 | 12.1 ± 26.3 | 16.8 ± 46.5 | 4.94 ± 0 | — | — | — | — |
| CL/F: Day 28 | — | — | — | — | — | — | — | — | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| CLss/F: Day 1 | 399 ± 19.9 | 318 ± 32.2 | 372 ± 23.3 | 434 ± 41.6 | 301 ± 57.5 | 264 ± 44.7 | 477 ± 117 | 502 ± 126 | 317 ± 89.3 | 263 ± 31.4 | 359 ± 97.1 | 1820 ± 45.0 |
| CLss/F: Day 21 | 39.9 ± 40.8 | 91.2 ± 42.5 | 85.7 ± 26.3 | 110 ± 38.6 | 74.7 ± 38.7 | 50.9 ± 23.1 | 77.8 ± 38.4 | 98.2 ± 50.4 | — | — | — | — |
| CLss/F: Day 28 | — | — | — | — | — | — | — | — | 57.4 ± 46.8 | 56.3 ± 35.5 | 63.8 ± 52.7 | 209 ± 117 |
Plasma samples were collected and used for pharmacokinetics assessments. Mean values of PK parameters are presented with the coefficient of variation (CV%).
| Ratio | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA, AUC0-24: Day 21 | 8.99 ± 46.9 | 3.72 ± 26.0 | 4.42 ± 18.3 | 3.91 ± 9.88 | 4.14 ± 50.2 | 4.48 ± 32.1 | 5.78 ± 85.6 | 4.92 ± 66.0 | — | — | — | — |
| RA, AUC0-24: Day 28 | — | — | — | — | — | — | — | — | 6.14 ± 33.9 | 5.81 ± 42.9 | 3.40 ± 36.9 | 9.33 ± 85.5 |
| RA, Cmax: Day 21 | 8.26 ± 49.1 | 3.08 ± 33.7 | 3.74 ± 42.5 | 3.54 ± 38.4 | 2.86 ± 69.4 | 3.07 ± 59.3 | 2.73 ± 52.5 | 4.06 ± 69.0 | — | — | — | — |
| RA, Cmax: Day 28 | — | — | — | — | — | — | — | — | 6.19 ± 44.4 | 3.75 ± 55.3 | 2.59 ± 29.6 | 2.13 ± 70.7 |
Urine samples were collected and used for pharmacokinetics (PK) assessments. Only cohorts with available data are presented. The assessment was performed only during the Phase I of the study. Mean values of PK parameters are presented with the coefficient of variation (CV%)
| percentage | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B:360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 21 | — | — | — | — | — | 0.0321 ± 76.4 | 0.0396 ± 137 | 0.0812 ± 49.4 | — | — | — | — |
| Day 28 | — | — | — | — | — | — | — | — | 0.0301 ± 42.2 | 0.0577 ± 67.4 | 0.0299 ± 44.9 | — |
For participants with AML diagnosis the number and percentage of participants with best response achieved on treatment in the following categories: CR, CRi, CRh, PR, MLFS, SD, No Response and Progressive Disease (PD). CR= complete response; CRh= Complete Remission with Partial Hematologic Recovery, CRi= Complete Remission with Incomplete Hematologic Recovery; CRc= Complete Remission Rate; MLFS= Morphologic leukemia free state; ORR= Overall Response Rate; PR= Partial Remission; SD= Stable Disease
| Participants | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Response/SD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 6 | 4 | 3 | 6 |
| CRc: CR + CRi | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CR+CRh+CRi | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| ORR:CR+CRh+CRi+MLFS+PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| CRi | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 1 |
| MLFS | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
Number of participants who achieved a CR as Best Response.
| Participants | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|
| For AML and in Phase II Only: Number of Participants Who Achieved Complete Remission (CR) | 0 | 0 |
Defined as the number of participants who achieved a CR or CRh or CRi as best response, divided by the number of participants in the analysis population.
| Participants | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|
| For AML and in Phase II Only: Complete Remission and Complete Remission With Partial Hematologic Recovery (CR/CRh) Rate | 0 | 0 |
Defined as the number of participants who achieved CRi or MLFS as best response, divided by the number of participants in the analysis population.
| Participants | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|
| For AML and in Phase II Only: Overall Response Rate (ORR: CRc + CRh + MLFS + PR) | 0 | 3 |
Defined as proportion of participants bridged to hemopoietic stem cell transplantation
| Participants | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg |
|---|---|---|
| Rate of Participants Bridged To Hemopoietic Stem Cell Transplantation | 0 | 1 |
Collected over Adverse events were collected from screening visit and assessed up to 18 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1, Schedule A: 20 mg | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1, Schedule A: 40 mg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1, Schedule A: 80 mg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1, Schedule A: 120 mg | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Phase 1, Schedule A: 180 mg | 3/3 (100%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1, Schedule A: 270 mg | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Phase 1, Schedule A: 300 mg | 9/10 (90%) | 8/10 (80%) | 10/10 (100%) |
| Phase 1, Schedule A: 360 mg | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Phase 1, Schedule B: 120 mg | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) |
| Phase 1, Schedule B: 180 mg | 6/6 (100%) | 6/6 (100%) | 6/6 (100%) |
| Phase 1, Schedule B: 250 mg | 4/4 (100%) | 4/4 (100%) | 3/4 (75%) |
| Phase 2, Schedule B: 360-150 mg | 9/15 (60%) | 14/15 (93.3%) | 14/15 (93.3%) |
| Event | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B: 360-150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 2/4 | 0/10 | 2/3 | 0/4 | 1/6 | 0/4 | 2/15 |
| Disease progressionGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 1/10 | 1/3 | 2/4 | 0/6 | 1/4 | 1/15 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 2/10 | 0/3 | 0/4 | 2/6 | 1/4 | 4/15 |
| DiplopiaEye disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/10 | 0/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| Decreased activityGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | 0/4 | 0/10 | 1/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| PyrexiaGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 1/10 | 0/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| Bronchopulmonary aspergillosisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 1/4 | 0/10 | 0/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| Lung infectionInfections and infestations | 0/3 | 1/3 | 0/3 | 0/3 | 0/3 | 0/4 | 2/10 | 0/3 | 1/4 | 0/6 | 0/4 | 0/15 |
| PharyngitisInfections and infestations | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 0/4 | 0/10 | 0/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| PneumoniaInfections and infestations | 0/3 | 0/3 | 1/3 | 0/3 | 0/3 | 1/4 | 0/10 | 0/3 | 0/4 | 0/6 | 0/4 | 2/15 |
| Event | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B: 360-150 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 3/3 | 1/3 | 1/3 | 2/4 | 2/10 | 1/3 | 0/4 | 2/6 | 0/4 | 0/15 |
| PyrexiaGeneral disorders | 2/3 | 0/3 | 2/3 | 0/3 | 1/3 | 1/4 | 0/10 | 3/3 | 2/4 | 2/6 | 3/4 | 5/15 |
| HyperphosphataemiaMetabolism and nutrition disorders | 0/3 | 0/3 | 3/3 | 0/3 | 0/3 | 1/4 | 0/10 | 0/3 | 1/4 | 0/6 | 0/4 | 1/15 |
| AstheniaGeneral disorders | 0/3 | 0/3 | 0/3 | 0/3 | 1/3 | 2/4 | 5/10 | 1/3 | 3/4 | 1/6 | 2/4 | 2/15 |
| LeukocytosisBlood and lymphatic system disorders | 2/3 | 1/3 | 1/3 | 0/3 | 0/3 | 1/4 | 1/10 | 0/3 | 0/4 | 1/6 | 0/4 | 0/15 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 2/3 | 0/3 | 2/3 | 0/4 | 0/10 | 1/3 | 2/4 | 1/6 | 0/4 | 1/15 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/3 | 2/3 | 1/3 | 1/3 | 2/4 | 1/10 | 2/3 | 0/4 | 2/6 | 1/4 | 2/15 |
| Sinus tachycardiaCardiac disorders | 0/3 | 0/3 | 2/3 | 0/3 | 0/3 | 0/4 | 0/10 | 0/3 | 0/4 | 0/6 | 0/4 | 0/15 |
| Abdominal pain upperGastrointestinal disorders | 2/3 | 0/3 | 2/3 | 0/3 | 2/3 | 0/4 | 1/10 | 1/3 | 1/4 | 0/6 | 0/4 | 1/15 |
| ConstipationGastrointestinal disorders | 0/3 | 0/3 | 2/3 | 1/3 | 1/3 | 1/4 | 1/10 | 1/3 | 0/4 | 1/6 | 0/4 | 2/15 |
Treated Participants: This population consisted of all enrolled participants who actually received at least 1 dose of study drug administration. This population was used for subject disposition, baseline characteristics, treatment exposure, efficacy, and safety. It is different from Participant Flow.
| Age, Categorical(Participants) | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 0 | 2 | 1 | 0 | 3 | 9 | 2 | 2 | 1 | 2 | 2 | 6 | 32 |
| >=65 years | 1 | 3 | 1 | 2 | 3 | 1 | 1 | 1 | 2 | 5 | 2 | 3 | 4 | 29 |
| Sex: Female, Male(Participants) | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 1 | 2 | 1 | 5 | 2 | 2 | 2 | 0 | 5 | 5 | 30 |
| Male | 2 | 1 | 1 | 2 | 1 | 3 | 5 | 1 | 2 | 4 | 4 | 0 | 5 | 31 |
| Race (NIH/OMB)(Participants) | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 3 | 3 | 3 | 3 | 4 | 10 | 3 | 4 | 6 | 4 | 4 | 9 | 58 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| (Eastern Cooperative Oncology Group Performance Status (ECOG-PS)(participants) | Phase 1, Schedule A: 20 mg | Phase 1, Schedule A: 40 mg | Phase 1, Schedule A: 80 mg | Phase 1, Schedule A: 120 mg | Phase 1, Schedule A: 180 mg | Phase 1, Schedule A: 270 mg | Phase 1, Schedule A: 300 mg | Phase 1, Schedule A: 360 mg | Phase 1, Schedule B: 120 mg | Phase 1, Schedule B: 180 mg | Phase 1, Schedule B: 250 mg | Phase 2, Schedule B, Cohort 1:360+150 mg | Phase 2, Schedule B, Cohort 2: 360+150 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ECOG PS = 0 | 0 | 1 | 1 | 0 | 3 | 2 | 4 | 0 | 3 | 2 | 2 | 1 | 4 | 23 |
| ECOG PS = 1 | 3 | 2 | 2 | 3 | 0 | 1 | 5 | 3 | 1 | 4 | 1 | 2 | 5 | 32 |
| ECOG PS = 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 1 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Aug 2024, 64 months.
Results were first posted in Mar 2026, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nerviano Medical Sciences